ENLV: שווי חברה לרווח נקי enlivex.com

This price chart for Enlivex Therapeutics (ENLV) allows for a valuation of a business whose potential is based on the creation of Allocetra to combat sepsis via macrophage modification. The current multiple is 0.00. Enlivex Therapeutics (ENLV) is also implementing methods to mitigate cytokine storms in intensive care units, ensuring a steady cash flow. The flawless organization of express biomaterial delivery between medical centers guarantees full operational reliability.
פילוחים אנליטיים של חברת Enlivex Therapeutics, Ltd. (ENLV)

The P/E ratio measures the market value of a single share relative to the annual net income per share, determining the investment payback period and the degree of asset overvaluation. For Enlivex Therapeutics (ENLV), whose profits depend on the implementation of sepsis therapy, the issuer's P/E ratio reflects market expectations for future payments for high-tech care, allowing for an assessment of the fundamental justification for current price fluctuations.